Entrada Therapeutics Inc (TRDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $199.28M
Last updated: Nov 17, 2026 at 11:05 AM ET
Entrada Therapeutics Inc (TRDA) Stock Forecast
Analysts expect Entrada Therapeutics (TRDA) to earn -$3.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $2.99M. Of 8 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 88% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 7 | 87.5% |
| Hold | 1 | 12.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 708.7%.
- Fiscal year ending Dec 31, 2026
- -$3.96
- EPS consensus, revenue $2.99M
- Fiscal year ending Dec 31, 2027
- -$3.40
- EPS consensus, revenue $24.18M
- Next report
- Feb 24, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$3.96 | -$4.05 to -$3.86 | 4 | $2.99M | $2.68M to $3.58M | 3 |
| Dec 31, 2027 | -$3.40 | -$4.16 to -$2.90 | 4 | $24.18M | $3.58M to $45.00M | 3 |
Quarterly Estimates
The EPS consensus rises from -$1.13 for the quarter ending Dec 31, 2026 to -$0.73 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.13 | -$1.85 to -$0.71 | 9 | $7.62M | N/A | 9 |
| Mar 31, 2027 | -$0.73 | -$1.10 to -$0.12 | 3 | $45.00M | $45.00M to $45.00M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.66.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.96 | -$3.93 | -$3.79 | -$3.79 | -$3.66 | N/A |
| Fiscal year ending Dec 31, 2027 | -$3.40 | -$3.24 | -$3.01 | -$3.01 | -$3.14 | N/A |
| Quarter ending Mar 31, 2027 | -$0.73 | -$0.75 | -$0.76 | -$0.76 | -$0.75 | N/A |
Frequently Asked Questions About TRDA
What is the TRDA stock forecast?
Consensus analyst estimates put Entrada Therapeutics's EPS at -$3.96 for the fiscal year ending Dec 31, 2026, on revenue of $2.99M. The consensus rating from 8 analysts is Buy.
How do analysts rate TRDA stock?
Of 8 analysts covering Entrada Therapeutics, 0 rate it Strong Buy, 7 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TRDA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.96, with estimates from -$4.05 to -$3.86 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$3.40, with estimates from -$4.16 to -$2.90 from 4 analysts.
What revenue do analysts expect from Entrada Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $2.99M, with estimates from $2.68M to $3.58M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $24.18M, with estimates from $3.58M to $45.00M.
How many analysts cover TRDA?
8 analysts rate Entrada Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TRDA pages: Overview, Earnings, Forecast, Financials, Competitors